Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLVE AML 001
2023-506865-71-00Phase 2Authorised
- Sponsor
- Advesya
- Start
- Feb 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of CCTx-001 in acute myeloid leukemia (AML), sponsored by Advesya. Primary endpoints: Frequency, severity, relationship and persistence of adverse events and dose-limiting toxicities (Phase 1) and Composite complete response rate (cCRR) (Phase 2). Planned start Feb 2024; status: authorised.
02
Drugs
CCTx-001
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-506865-71-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506865-71-00.